Archive: 28/12/2011

Avastin disappoints against ovarian cancer

Avastin, the blockbuster drug that just lost approval for treating breast cancer, now looks disappointing against ovarian cancer, too. Two studies found it did not improve survival for most of these patients and kept their ...

The perils of 'bite-size' science

Short, fast, and frequent: Those 21st-century demands on publication have radically changed the news, politics, and culture—for the worse, many say. Now an article in January's Perspectives on Psychological Science, ...

page 1 from 3